Physician profile
Thomas A Brooks
NPI 1346293651
$13,286.00
in general payments reported to CMS, 2019-2025
28 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,719 · 2020: $1,680 · 2021: $1,740 · 2022: $1,359 · 2023: $2,365 · 2024: $1,659 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648 · Travel and Lodging: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.05 |
| Travel and Lodging | $1,139.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $6,284.56 | 2019-2024 | Senza |
| Medtronic, INC. | $1,743.28 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Spr Therapeutics, INC | $1,403.60 | 2021-2025 | Sprint Pns System |
| Relievant Medsystems, INC. | $1,287.59 | 2023 | Intracept |
| Si-Bone, INC. | $792.17 | 2020-2025 | |
| Boston Scientific Corporation | $412.09 | 2020-2025 | Intracept, Patient Trial Kit |
| Globus Medical, INC. | $295.70 | 2025 | Senza |
| Painteq LLC | $183.64 | 2022 | |
| Abbott Laboratories | $117.74 | 2021-2023 | Proclaim |
| Medtronic USA, INC. | $98.03 | 2019-2020 | |
| Forte Bio-Pharma LLC | $95.78 | 2022-2024 | Prolate, Nalocet |
| Arbor Pharmaceuticals, INC. | $72.47 | 2020-2021 | |
| Abbvie INC. | $58.00 | 2023-2024 | Ubrelvy, Botox |
| Pfizer INC. | $55.50 | 2023-2024 | |
| Lilly USA, LLC | $48.69 | 2021-2023 | Emgality |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $47.47 | 2020-2024 | Vyepti |
| Spinal Simplicity, LLC | $46.71 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $40.31 | 2021 | |
| Impel Pharmaceuticals INC. | $35.18 | 2023 | Trudhesa |
| Stryker Corporation | $25.36 | 2019 | |
| Saluda Medical Americas, INC. | $25.27 | 2024 | Evoke |
| Djo, LLC | $22.21 | 2024 | Cmf |
| Grt US Holding, INC. | $21.24 | 2022 | |
| Nalu Medical, INC. | $19.18 | 2024 | Nalu Neurostimulation System |
| Kowa Pharmaceuticals America, INC. | $15.31 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.55 | 2020 | |
| Avanos Medical | $13.15 | 2020 | |
| Biodelivery Sciences International, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.